Antimicrobial chemotherapy for legionnaires' disease: a review

Clin Infect Dis. 1995 Dec:21 Suppl 3:S265-76. doi: 10.1093/clind/21.supplement_3.s265.

Abstract

Controlled trials of antimicrobial chemotherapy for legionnaires' disease have not been performed, although erythromycin and tetracycline appear to be effective therapies. Laboratory data indicate that the activities of the fluoroquinolone and newer macrolide/azalide agents against Legionella pneumophila are superior to that of erythromycin, and case reports substantiate that the activities of these agents are at least equal. Results of clinical treatment with and laboratory testing of macrolides, tetracyclines, co-trimoxazole, chloramphenicol, aminoglycosides, fluoroquinolones, beta-lactam agents, and streptogramins are reviewed. The drugs of choice for the treatment of legionnaires' disease in immunocompromised or severely ill patients should be one of the fluoroquinolone antimicrobials rather than erythromycin.

Publication types

  • Review

MeSH terms

  • 4-Quinolones
  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents / therapeutic use
  • Antifungal Agents / therapeutic use
  • Drug Evaluation, Preclinical
  • Female
  • Guinea Pigs
  • Humans
  • Legionella pneumophila / drug effects
  • Legionnaires' Disease / drug therapy*
  • Legionnaires' Disease / mortality
  • Male
  • Microbial Sensitivity Tests / methods

Substances

  • 4-Quinolones
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antifungal Agents